CH622261A5 - - Google Patents

Download PDF

Info

Publication number
CH622261A5
CH622261A5 CH388676A CH388676A CH622261A5 CH 622261 A5 CH622261 A5 CH 622261A5 CH 388676 A CH388676 A CH 388676A CH 388676 A CH388676 A CH 388676A CH 622261 A5 CH622261 A5 CH 622261A5
Authority
CH
Switzerland
Prior art keywords
formula
compound
compounds
methyl
preparation
Prior art date
Application number
CH388676A
Other languages
German (de)
English (en)
Inventor
Willem Jacob Van Der Burg
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19823518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CH622261(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of CH622261A5 publication Critical patent/CH622261A5/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CH388676A 1975-04-05 1976-03-29 CH622261A5 (pm)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NLAANVRAGE7504075,A NL189199C (nl) 1975-04-05 1975-04-05 Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.

Publications (1)

Publication Number Publication Date
CH622261A5 true CH622261A5 (pm) 1981-03-31

Family

ID=19823518

Family Applications (1)

Application Number Title Priority Date Filing Date
CH388676A CH622261A5 (pm) 1975-04-05 1976-03-29

Country Status (17)

Country Link
US (1) US4062848A (pm)
JP (1) JPS5942678B2 (pm)
BE (1) BE840362A (pm)
CA (1) CA1076571A (pm)
CH (1) CH622261A5 (pm)
DE (1) DE2614406A1 (pm)
DK (1) DK142498B (pm)
ES (2) ES446634A1 (pm)
FI (1) FI62087C (pm)
FR (1) FR2305986A1 (pm)
GB (1) GB1543171A (pm)
HU (1) HU179401B (pm)
IE (1) IE42969B1 (pm)
LU (1) LU74680A1 (pm)
NL (2) NL189199C (pm)
SE (1) SE422941B (pm)
ZA (1) ZA761756B (pm)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515792A (en) * 1982-09-30 1985-05-07 Ciba-Geigy Corporation Tetracyclic heterocycles and antidepressant compositions thereof
JPS6336682A (ja) * 1986-07-31 1988-02-17 Matsushita Electric Ind Co Ltd カセツト方式文字放送受信機
JPS63177670A (ja) * 1987-01-31 1988-07-21 Fujitsu General Ltd 文字放送受信装置
JPS63215179A (ja) * 1987-03-03 1988-09-07 Fujitsu General Ltd 受信装置
RU2048469C1 (ru) * 1989-10-05 1995-11-20 Санкио Компани Лимитед Способ получения азетидинового производного или его фармацевтически приемлемой соли
EP0539164A1 (en) * 1991-10-23 1993-04-28 Sankyo Company Limited Nitrogen-containing tetracyclic compounds having anti-allergic and anti-asthmatic activities, their preparation and use
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
WO1999051237A1 (en) * 1998-04-02 1999-10-14 Akzo Nobel N.V. Oral liquid antidepressant solution
WO2000062782A1 (en) * 1999-04-19 2000-10-26 Teva Pharmaceutical Industries Ltd. Novel synthesis and crystallization of piperazine ring-containing compounds
US6545149B2 (en) * 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
AU781221B2 (en) * 1999-04-19 2005-05-12 Teva Pharmaceutical Industries Ltd. Novel synthesis and crystallization of piperazine ring-containing compounds
PL351395A1 (en) 1999-04-19 2003-04-07 Teva Pharma Novel synthesis of piperazine ring
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
WO2001025185A1 (fr) * 1999-09-30 2001-04-12 Sumika Fine Chemicals Co., Ltd. Procede de production de derive de piperazine
WO2001038329A1 (fr) * 1999-11-24 2001-05-31 Sumika Fine Chemicals Co., Ltd. Cristaux de mirtazapine anhydre et leur procede d'obtention
AU6474200A (en) 1999-12-13 2001-06-18 Sumika Fine Chemicals Co., Ltd. Process for the preparation of a pyridinemethanol compound
JP2003520237A (ja) * 2000-01-19 2003-07-02 アクゾ・ノベル・エヌ・ベー 鬱病及び関連疾患を治療するためのミルトラザピン及びジェピロンを含有する配合剤
EP2283840A1 (en) 2000-02-11 2011-02-16 N.V. Organon The use of mirtazapine for the treatment of sleep disorders.
IN190478B (pm) * 2000-11-07 2003-08-02 Sun Pharmaceutical Ind Ltd
US6660730B2 (en) * 2000-11-27 2003-12-09 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine and process for preparing the same
ES2296893T3 (es) * 2001-02-12 2008-05-01 N.V. Organon Uso de mirtazapina para el tratamiento de la depresion severa en un paciente humano y portador del gen de la apolipoproteina e4.
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
KR20030078086A (ko) * 2001-03-01 2003-10-04 테바 파마슈티컬 인더스트리즈 리미티드 미르타자핀 중간체의 제조방법
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
CZ296992B6 (cs) * 2002-10-03 2006-08-16 Zentiva, A.S. Príprava a izolace 2-substituovaných-3-pyridylkarboxylových kyselin, jejich karboxylových solí a produktu redukce
WO2004084905A2 (en) * 2003-03-24 2004-10-07 University Of Florida Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions
UA83666C2 (ru) 2003-07-10 2008-08-11 Н.В. Органон Способ получения энантиомерно чистого миртазапина
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
EP1753460A2 (en) * 2004-05-11 2007-02-21 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
AU2005272773A1 (en) * 2004-08-13 2006-02-23 Omeros Corporation Novel serotonin receptor ligands and their uses thereof
WO2006023702A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders with setiptiline
JP4848704B2 (ja) * 2004-08-24 2011-12-28 住友化学株式会社 2−(4−メチル−2−フェニルピペラジン−1−イル)−3−シアノピリジンの製造方法
WO2006022182A1 (ja) * 2004-08-24 2006-03-02 Sumitomo Chemical Company, Limited 2-(4-メチル-2-フェニルピペラジン-1-イル)-3-シアノピリジンの製造方法
TW200631584A (en) * 2004-11-15 2006-09-16 Akzo Nobel Nv A medicament related to mirtazapine for the treatment of hot flush
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
US20090306046A1 (en) * 2005-06-27 2009-12-10 N.V. Organon Method of treatment of hormone depletion induced vasomotor symptoms
CA2614289A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
CN1939918B (zh) * 2005-09-30 2010-09-01 北京德众万全医药科技有限公司 一种米氮平的制备方法
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CN101355876B (zh) 2005-11-09 2012-09-05 康宾纳特克斯公司 一种适用于眼部给药的组合物
EP1953150A4 (en) * 2005-11-14 2009-11-04 Sumitomo Chemical Co PROCESS FOR PREPARING 2- (4-METHYL-2-PHENYLPIPERAZIN-1-YL) PYRIDINE-3-METHANOL
EP1792618A1 (en) 2005-11-30 2007-06-06 Rainer Freynhagen R-mirtazapine for the treatment of pain
WO2007101832A1 (en) * 2006-03-06 2007-09-13 N.V. Organon An improved method of weaning from hormonal treatment of hormone depletion induced vasomotor symptoms
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US20070270413A1 (en) * 2006-05-22 2007-11-22 N.V. Organon Mirtazapine for the treatment of neuropathic pain
TW200815370A (en) * 2006-06-16 2008-04-01 Organon Nv Stereoselective synthesis of (S)-1-methyl-3-phenylpiperazine
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
EP2125017A2 (en) * 2007-01-11 2009-12-02 Braincells, Inc. Modulation of neurogenesis with use of modafinil
JP5192707B2 (ja) * 2007-03-22 2013-05-08 住友化学株式会社 ミルタザピンの製造方法
AR066004A1 (es) * 2007-04-11 2009-07-15 Organon Nv Un metodo para la preparacion de una benzazepina enantiomericamente pura
CA2684021A1 (en) * 2007-04-11 2008-10-23 N.V. Organon A method for the preparation of an enantiomer of a tetracyclic benzazepine
US7994314B2 (en) * 2007-04-11 2011-08-09 N.V. Organon Method for the preparation of an enantiomerically pure benzazepine
US20080255348A1 (en) * 2007-04-11 2008-10-16 N.V. Organon Method for the preparation of an enantiomer of a tetracyclic benzazepine
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
JP2009018992A (ja) * 2007-07-10 2009-01-29 Sumitomo Chemical Co Ltd 光学活性ミルタザピンの製造方法
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2321011A1 (en) * 2008-06-25 2011-05-18 Pfizer Inc. Diaryl compounds and uses thereof
US20110201804A1 (en) * 2008-10-22 2011-08-18 Watson Pharma Private Limited Process for the preparation of 1- ( 3-hydroxymethylpyrid-2 -yl ) -2 -phenyl-4-methylpiperazine and mirtazapine
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102432594B (zh) * 2011-11-28 2013-09-11 山东鲁药制药有限公司 一种药物中间体1-(3-羟甲基吡啶-2-基)-2-苯基-4-甲基哌嗪的制备方法
CN103509020A (zh) * 2013-10-21 2014-01-15 山东鲁药制药有限公司 一种米氮平的合成方法
CN104356133A (zh) * 2014-11-25 2015-02-18 南京工业大学 一种制备抗抑郁药物米氮平的方法
JP6433809B2 (ja) * 2015-02-20 2018-12-05 株式会社トクヤマ 1−(3−ヒドロキシメチルピリジル−2−)−2−フェニル−4−メチルピペラジンの製造方法
KR102540021B1 (ko) 2020-12-02 2023-06-07 (주)유케이케미팜 대량 생산에 적합한 미르타자핀의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129434C (pm) * 1966-03-12
NL7202963A (pm) * 1972-03-07 1973-09-11
US3959470A (en) * 1972-11-28 1976-05-25 Mikhail Davidovich Mashkovsky Psychotropic medicinal preparation

Also Published As

Publication number Publication date
JPS51122099A (en) 1976-10-25
ES459348A1 (es) 1978-03-16
IE42969L (en) 1976-10-05
SE422941B (sv) 1982-04-05
HU179401B (en) 1982-10-28
NL189199B (nl) 1992-09-01
FI62087B (fi) 1982-07-30
ES446634A1 (es) 1977-11-01
FI760884A7 (pm) 1976-10-06
FI62087C (fi) 1982-11-10
DE2614406A1 (de) 1976-10-14
DK142498C (pm) 1981-07-06
DK142498B (da) 1980-11-10
BE840362A (fr) 1976-10-04
US4062848A (en) 1977-12-13
FR2305986A1 (fr) 1976-10-29
JPS5942678B2 (ja) 1984-10-16
CA1076571A (en) 1980-04-29
AU1236176A (en) 1977-09-29
NL189199C (nl) 1993-02-01
DK142676A (pm) 1976-10-06
DE2614406C2 (pm) 1992-02-20
FR2305986B1 (pm) 1980-06-13
NL7504075A (nl) 1976-10-07
NL940007I1 (nl) 1994-06-01
ZA761756B (en) 1977-03-30
LU74680A1 (pm) 1976-11-11
NL940007I2 (nl) 1994-10-17
GB1543171A (en) 1979-03-28
SE7603931L (sv) 1976-10-06
IE42969B1 (en) 1980-11-19

Similar Documents

Publication Publication Date Title
CH622261A5 (pm)
DE69723846T2 (de) Verfahren zur Herstellung von Sildenafil
CH637382A5 (de) Verfahren zur herstellung neuer tetracyclischer pyridin- oder pyrrolderivate.
DE2111071A1 (de) Verfahren zur Herstellung neuer heterocyclischer Verbindungen
DE1795769B2 (de) 6,7A9-Tetrahydro-2H-pyrido [1,2-a] pyrimidinderivate, deren Salze mit Säuren und quaternär? Methosalze, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Arzneimittel
DE2505239C2 (pm)
DE1670849B2 (de) Verfahren zur herstellung von 8-acylamino-1,2,3,4-tetrahydroisochinolinen
DE68903680T2 (de) 6-phenyl-3-piperazinylalkyl-1h,3h-pyrimidindion-2,4-derivate, deren herstellung und verwendung als heilmittel.
DE1695929C3 (de) 1 ^-Dihydro-1 -hydroxy^-imino^-amino-6-methylpyrimidine sowie ein Verfahren zu deren Herstellung
DE2141616A1 (de) Verfahren zur Herstellung von Chinazo lindenvaten und neue Chinazolindenvate
DE1967178C2 (de) Verfahren zur Herstellung von Chinuclidinyl-4-chinolinmethanolderivaten
DE1935671C3 (de) 2-Aminomethylindole und ihre Salze
CH630902A5 (en) Process for preparing novel derivatives of 1,2,3,4,4a,10b-hexahydrobenzo(f)isoquinoline.
DE1076691B (de) Verfahren zur Herstellung von Phenthiazinderivaten
DE2230154A1 (de) N-(heteroaryl-methyl)-6,14-endoaetheno7alpha-hydroxyalkyl-tetrahydro-nororipavine und -thebaine, deren hydrierungsprodukte und saeureadditionssalze sowie verfahren zu deren herstellung
EP0102318A2 (de) Herstellung von beta-Amino-alpha,beta-ungesättigten Carbonsäureestern
DE2511599A1 (de) Pyrroldiazepine und verfahren zu ihrer herstellung
DE3120909C2 (de) Verfahren zur Herstellung von 7-(N-Äthyl-N-β-hydroxyäthylaminoäthyl)-8-benzyltheophyllin (Bamifyllin)
DE1038047B (de) Verfahren zur Herstellung von N-aminoalkylierten Iminodibenzylen und deren Salzen
DE1795053A1 (de) Verfahren zur Herstellung von Verbindungen der Benzodiazepinreihe
AT330373B (de) Verfahren zur herstellung von neuen 2- (heteroaryl-methyl) -5,9beta-dialkyl -6,7- benzomorphanen
AT378960B (de) Verfahren zur herstelllung von neuen imidazo (1,5-a) (1,4)diazepinverbindungen, ihren salzen und optisch aktiven formen
CH561211A5 (en) Antihypertensive 3-hydrazino pyrido(4,3-c)pyridazines - prepd. by reacting corresp 3-halo cpd. with hydrazines
AT317231B (de) Verfahren zur Herstellung von neuen Diazepinderivaten sowie deren 5-Oxyden und deren Säureadditionssalzen
AT251765B (de) Verfahren zur Herstellung von neuen Yohimbanderivaten und von deren Salzen

Legal Events

Date Code Title Description
PL Patent ceased